Bayer

Summary

Bayer is a global enterprise, headquartered in Germany, with core competencies in the fields of healthcare, nutrition and high-tech materials, and organised into three subgroups, namely HealthCare, CropScience and MaterialScience. Following Bayer's acquisition of Schering AG on 23rd June 2006, Schering was renamed Bayer Schering Pharma and its integration into the Pharmaceuticals division of Bayer HealthCare is now under way. Bayer Schering Pharma is expected to contribute to over half the revenues of Bayer HealthCare.

Bayer HealthCare's combined pharmaceuticals business is characterised by a well-balanced portfolio comprised of business units such as oncology, cardiology/haematology and gynaecology. In addition, the combined biotech platform provides a sound basis for further growth, including such products as Schering's Betaseron (interferon beta-1b) and Leukine (sargramostim), together with Bayer's genetically-engineered Factor VIII Kogenate. Current growth drivers include: Avalox/Avelox (moxifloxacin), Betaferon/Betaseron (interferon beta-1b), Kogenate (Factor VIII), Levitra (vardenafil), Mirena (levonorgestrel), Yasmin (ethinyloestradiol+drospirenone) and Aspirin Cardio. By combining and consolidating the research and development activities of the two companies Bayer has achieved a more focused and balanced pipeline.

Overall, the Bayer Group is focusing on the fast-growing, innovation-driven healthcare, nutrition and high-tech materials businesses, aiming to achieve leadership roles and expand its strong market positions. In addition, it is pressing ahead with cost-containment and efficiency improvements.

Bayer currently has a particular focus on HealthCare and its goal is to match or exceed market growth in both Pharmaceuticals and Consumer OTC. Within its largest segment of Pharmaceuticals, the acquisition of Schering AG has strengthened the company's global market position and it is aiming to become one of the top ten worldwide pharma companies. It is aiming to grow the pharmaceuticals business in line with the market between 2007 and 2009, at 5-6 per cent per annum, and then accelerate.

Contents

• Executive Summary
  • A Detailed and Comprehensive Overview of Current Financial Position, Company Strategy, Product and Pipeline Analysis.
• Therapeutic Area Focus
  • Key Product Analysis and Forecasting
• Primary Care
  • Adalat (Nifedipine)
  • Avelox/Avalox (Moxifloxacin)
  • Cipro/Ciprobay (Ciprofloxacin)
  • Glucobay (Acarbose)
  • Kinzalmono (Telmisartan)
  • Levitra/Vivanza (Vardenafil)
• Women's Healthcare
  • Angeliq (Drospirenone+Oestradiol)
  • Mirena (Levonorgestrel)
  • Yasmin (Drospirenone+Ethinyloestradiol)
• Diagnostic Imaging
  • Magnevist (Gadopentetate Meglumine)
  • Vasovist (Gadolinium-Chelate)
• Specialized Therapeutics
  • Betaferon/Betaseron (Interferon Beta-1b)
  • Sativex (Delta-9-Tetrahydrocannabinol+Cannabidiol)
• Hematology/Cardiology
  • Kogenate/Kogenate Fs (Factor Viii)
  • Recothrom (Recombinant Human Thrombin [Rthrombin])
  • Trasylol (Aprotinin)
• Oncology
  • Campath/Mabcampath (Alemtuzumab)
  • Fludara (Fludarabine)
  • Nexavar (Sorafenib)
  • Zevalin (Ibritumomab Tiuxetan)
• Operational Data
  • A Wealth of Background and Detail
  • A Full 5-Year Financial Performance Assessment
  • Key Agreements
  • Infrastructure
  • Subsidiaries and Joint Ventures